JPMorgan raised the firm’s price target on Kymera Therapeutics (KYMR) to $125 from $70 and keeps an Overweight rating on the shares following the Phase 1b BroADen atopic dermatitis data. The firm increased Kymera’s probability of success to to 40% and 30% in atopic dermatitis and asthma, respectively.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics 7M share Secondary priced at $86.00
- Kymera Therapeutics price target raised to $122 from $73 at Jefferies
- Kymera Therapeutics falls -9.2%
- Kymera Therapeutics price target raised to $116 from $80 at Truist
- Kymera Therapeutics’ KT-621: Promising Oral Treatment for Atopic Dermatitis and Asthma Expansion Potential